ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 836

B Cell Receptor Sequencing of Anti-Citrullinated Protein Antibody Expressing B Cells Indicates a Selective Advantage for the Introduction of N-Glycosylation Sites during Somatic Hypermutation

Rochelle D. Vergroesen1, Linda Slot1, Lise Hafkenscheid1, Marvyn T. Koning2, Ellen I.H. van der Voort3, Christine A. Grooff1, George Zervakis2, Tom W.J. Huizinga1, Theo Rispens4, Hendrik Veelken2, Rene E.M. Toes1 and Hans U. Scherer3, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Hematology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Immunopathology, Sanquin Research, Amsterdam, Netherlands

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: ACPA, B cell tolerance, B cells and rheumatoid arthritis (RA)

Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

The vast majority (>90%) of anti-citrullinated protein antibodies (ACPA) of the IgG isotype in serum and synovial fluid of patients with rheumatoid arthritis carry N-linked glycans in the antibody variable region. This remarkable degree of Fab-glycosylation is absent from ACPA-depleted control IgG and from autoantibodies in other diseases. N-glycosylation requires a specific amino acid consensus sequence in the protein backbone (termed an N-glycosylation site), which is very rare in germline-encoded variable region genes. Here, we analysed the B cell receptor (BCR) repertoire of ACPA-expressing B cells to understand the molecular basis for this remarkable glycosylation.

Methods:

We used anchoring reverse transcription of immunoglobulin (Ig) sequences and amplification by nested PCR (ARTISAN) to obtain full-length rearrangements of ACPA-expressing B cells. ACPA-expressing B cells and non citrulline-reactive control B cells were obtained from peripheral blood of patients with established RA by antigen-specific tetramer staining and fluorescence activated cell sorting. Cells were either sorted in pools, or sorted as single cells. Somatic mutations and N-glycosylation sites were identified in the sequence reads using IMGT (High)V-QUEST. Paired heavy and light chain sequences (HC/LC) were used to model the spatial positioning of N-glycosylation sites.

Results:

Sequence analysis of pools of cells identified 97 unique ACPA-IgG clones derived from n=8 donors. 87 unique ACPA-IgG clones were retrieved from single cell analysis (n=6 donors). In both datasets, over 80% of ACPA-IgG clones contained N-glycosylation sites in both HC and LC. All sites were created by somatic mutations. The mutation rate did not correlate with the number of N-glycosylation sites, and their distribution across the variable region and their preference differed from the pattern seen in controls. Structural modelling predicted N-glycosylation sites on the exterior of the antibody molecule.

Conclusion:

ACPA-expressing B cells generate BCRs with a high frequency of N-glycosylation sites. Frequency and localization of sites suggest that ACPA-expressing B cells gain a selective survival advantage by acquiring glycans in the variable domain, thereby escaping from putative checkpoints in B cell selection.


Disclosure: R. D. Vergroesen, None; L. Slot, None; L. Hafkenscheid, None; M. T. Koning, None; E. I. H. van der Voort, None; C. A. Grooff, None; G. Zervakis, None; T. W. J. Huizinga, None; T. Rispens, None; H. Veelken, None; R. E. M. Toes, None; H. U. Scherer, None.

To cite this abstract in AMA style:

Vergroesen RD, Slot L, Hafkenscheid L, Koning MT, van der Voort EIH, Grooff CA, Zervakis G, Huizinga TWJ, Rispens T, Veelken H, Toes REM, Scherer HU. B Cell Receptor Sequencing of Anti-Citrullinated Protein Antibody Expressing B Cells Indicates a Selective Advantage for the Introduction of N-Glycosylation Sites during Somatic Hypermutation [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/b-cell-receptor-sequencing-of-anti-citrullinated-protein-antibody-expressing-b-cells-indicates-a-selective-advantage-for-the-introduction-of-n-glycosylation-sites-during-somatic-hypermutation/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/b-cell-receptor-sequencing-of-anti-citrullinated-protein-antibody-expressing-b-cells-indicates-a-selective-advantage-for-the-introduction-of-n-glycosylation-sites-during-somatic-hypermutation/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology